Palomar - the first company to obtain clearance from the Food and Drug Administration (FDA) for 'permanent hair reduction' - will present its latest products at the American Academy of Dermatology's annual meeting in Washington, from 7-10 February.
The Palomar portfolio currently includes the MediLux, >EsteLux and NeoLux, which are sold with the LuxY handpiece for hair removal and pigmented lesion treatment on large body areas, the LuxG handpiece for photofacial treatments on vascular and pigmented lesions and the LuxR handpiece for large-area hair removal on all skin types.
Last year, Palomar and the Gillette Company entered into an agreement to complete development and to commercialise a patented home-use, light-based hair removal device for women.
New innovatives are also being tested by the company, claimed to further advance the hair removal market and other cosmetic applications, including fat reduction, acne treatment and skin rejuvenation. For example, the LuxV handpiece for fast treatment of pigmented lesions and mild to moderate acne is pending FDA clearance.
With the various Lux handpieces Palomar claims that physicians can tailor a system to their existing practice or offer additional applications to their patients at a fraction of competing systems.
Palomar pioneered the optical hair removal field in 1997 when it introduced the first high-powered laser hair removal system. The market acceptance of the Lux family of products has helped the company to increase revenues, profit and cash positioning over the last few years.
Palomar also sells the Q-YAG 5 laser system for tattoo and pigmented lesion removal.